15 completed, 3 unknown, 2 recruiting. 20 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Completed 15, Unknown 3, Recruiting 2 |
| Phase 2 | 1 | Unknown 1 |
Follow GERD: new trials by email Literature Review of GERD trials Research Report on GERD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers. Trimedat® - Irritable Bowel Syndrome, Gallstone Disease | Phase 1 | Recruiting | Valenta Pharm JSC | 36 | 2025-11-06 | 2026-02-19 |
| A Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of UI059 and UIC202201 in Healthy Subjects UI059, UIC202201 - GERD | Phase 1 | Completed | Korea United Pharm. Inc. | 8 | 2023-10-08 | 2023-11-21 |
| Investigate Linaprazan Glurate/Linaprazan in Healthy Subjects linaprazan glurate 25 mg QD, linaprazan glurate 50 mg QD, linaprazan glurate 75 mg QD - GERD | Phase 1 | Completed | Cinclus Pharma Holding AB | 75 | 2023-01-26 | 2025-05-07 |
| A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate Linaprazan glurate, Placebo - Pharmacokinetics, Cardiodynamic ECG | Phase 1 | Recruiting | Cinclus Pharma Holding AB | 121 | 2022-07-13 | 2026-06-17 |
| A Study to Evaluate the PK, PD and Safety of CKD-382 in Healthy Subjects CKD-382, D860, D027 - GERD | Phase 1 | Unknown | Chong Kun Dang Pharmaceutical | 42 | 2021-10-07 | 2021-11-04 |
| A Study to Investigate the Effect of Food on the PK, PD of CKD-381 in Healthy Volunteers CKD-381 - GERD | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 28 | 2021-04-21 | 2021-08-18 |
| Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 PurWet, FurFat, PurApo - Sequelae of; Infection, Post Infection Glomerulonephritis | Phase 1 / Phase 2 | Unknown | All Natural Medicine Clinic, LLC | 2000 | 2021-03-01 | 2021-05-26 |
| A Study to Compare PK, PD and Safety of UI058 and UIC202004 in Healthy Subjects administration of UI058, administration of UIC202004 - GERD | Phase 1 | Completed | Korea United Pharm. Inc. | 41 | 2021-02-03 | 2024-07-03 |
| A Study to Compare PK, PD and Safety of CKD-382 in Healthy Subjects CKD-382(formulation I), CKD-382(formulation II), D026 - GERD | Phase 1 | Unknown | Chong Kun Dang Pharmaceutical | 48 | 2020-09-25 | 2021-01-11 |
| Clinical Trial to Assess the PK/PD of YYD601 20mg After Oral Administration if Healthy Adult Subjects (Phase1) YYD601 20mg, Nexium tab 20mg - GERD | Phase 1 | Completed | Yooyoung Pharmaceutical Co., Ltd. | 28 | 2019-07-08 | 2021-05-11 |
| A Study to Compare PK, PD and Safety of CKD-381 and D026 in Healthy Subjects CKD-381, D026 - GERD | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 41 | 2018-06-27 | 2018-10-12 |
| A Study to Compare PK and Safety of CKD-381 and D026 in Healthy Male Subjects CKD-381(formulation I), CKD-381(formulation II), D026(Nexium 40mg) - GERD | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 18 | 2018-03-02 | 2018-05-24 |
| PK/PD Clinical Trial of YYD601 in Healthy Adult Male YYD601 1, YYD601 2, YYD601 3 - GERD | Phase 1 | Completed | Yooyoung Pharmaceutical Co., Ltd. | 30 | 2017-09-19 | 2018-06-15 |
| A Study to Compare PK, PD and Safety of CKD-381 in Healthy Subjects CKD-381, Nexium - GERD | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 41 | 2017-06-20 | 2017-11-21 |
| Can Quercetin Increase Claudin-4 and Improve Esophageal Barrier Function in GERD? Quercetin - Gastroesophageal Reflux Disease, GERD | Phase 1 | Completed | University of North Carolina, Chapel Hill | 26 | 2014-08-01 | 2016-12-20 |
| Pharmacokinetics of Pantoprazole and CYP2C19 Activity in Children and Adolescents With GERD: A Pilot Study Pantoprazole - Obesity, GERD | Phase 1 | Completed | Children's Mercy Hospital Kansas City | 71 | 2013-06-01 | 2021-12-03 |
| A Study of the Effect of ONO-8539 on Oesophageal Pain Hypersensitivity in Patients With Non-erosive Reflux Disease ONO-8539, Placebo - GERD | Phase 1 | Completed | Ono Pharmaceutical Co., Ltd. | 14 | 2012-12-01 | 2015-10-14 |
| A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabreprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Years Old, Inclusive Rabeprazole sodium - GERD | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 31 | 2008-03-01 | 2011-01-10 |
| Acid Reflux and Stromal Fibroblasts in Barrett's Esophagus Endoscopy and pH study - Barrett's Esophagus, GERD | Phase 1 | Completed | Mayo Clinic | 16 | 2007-08-01 | 2013-01-17 |
| A Study to Monitor Intragastric pH in Patients Taking Rabeprazole vs. Patients Taking Pantoprazole rabeprazole sodium - GERD | Phase 1 | Completed | Janssen-Ortho Inc., Canada | 37 | 2005-10-01 | 2012-12-10 |
Gastroesophageal Reflux (20) · Ageusia (1) · Anosmia (1) · Anxiety Disorders (1) · Arthritis, Reactive (1) · Barrett Esophagus (1) · Biliary Dyskinesia (1) · Bipolar Disorder (1) · COVID-19 stress syndrome (1) · Cholelithiasis (1) · Depression (1) · Glomerulonephritis (1) · Guillain-Barre Syndrome (1) · Heartburn (1) · Hepatitis (1)
Deglutition Disorders (20) · Digestive System Diseases (20) · Esophageal Diseases (20) · Esophageal Motility Disorders (20) · Gastrointestinal Diseases (20) · Pathological Conditions, Signs and Symptoms (3) · Pathologic Processes (2) · Signs and Symptoms (2) · Arthritis (1) · Arthritis, Infectious (1) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Behavior (1) · Behavioral Symptoms (1) · Bile Duct Diseases (1)
Esomeprazole (3) · Rabeprazole (2) · BID protein, human (1) · Drugs, Investigational (1) · Endoscopy (1) · ONO-8539 (1) · Pantoprazole (1) · Quercetin (1) · Trimebutine (1)
Chong Kun Dang Pharmaceutical (6) · Cinclus Pharma Holding AB (2) · Korea United Pharm. Inc. (2) · Yooyoung Pharmaceutical Co., Ltd. (2) · All Natural Medicine Clinic, LLC (1) · Children's Mercy Hospital Kansas City (1) · Janssen-Ortho Inc., Canada (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · Mayo Clinic (1) · Ono Pharmaceutical Co., Ltd. (1) · University of North Carolina, Chapel Hill (1) · Valenta Pharm JSC (1)
South Korea (10) · United States (4) · Belgium (1) · Russia (1) · Slovenia (1) · Sweden (1) · United Kingdom (1)
Choon Ok Kim, MD (1) · Craig Friesen, MD (1) · Erik Rein-Hedin, MD (1) · Kyung Sang Yu, M.D (1) · Kyung Sang Yu, M.D., Ph.D. (1) · Kyungsang Yu, M.D., Ph.D. (1) · Min Kyu Park, Dr (1) · Minkyu Park, Dr (1) · Nicholas Shaheen, MD, MPH (1) · Prasad G Iyer, M.D. (1) · Tanja Turk, M.Pharm (1) · Wanzhu Hou, CMD (1)
PMID 17116123, PMID 30257076, PMID 31564831, PMID 35281316, PMID 39803609
R21DK097529 (1)